Ewing’s Sarcoma as a Second Malignancy in Long-Term Survivors of Childhood Hematologic Malignancies

Table 1

Clinical data on the patients in the current study.

Pat.	Gender	Age at Dx (T-ALL)	Age at Dx (ES)	Latency (y)	Location of ES	Treatment of the primary hematological malignancy
						Anthracyclines, TPII-Inh	Vinca	Alkylating agent	Antimetabolite	RT
1	m	5	8	3	Paravertebral (L5)	ADR	None	CPA, IFO	Ara-C	None
2	m	16	21	5	Brain, temporal lobe	DNR	VCR	CPA	MTX, Ara-C, 6-MP, 6-TG	Whole brain (12 Gy)
3	f	9	11	2	Mandible	DNR	VCR	CPA	MTX, Ara-C, 6-MP, 6-TG	Whole body (12 Gy)

DNR, daunorubicin; ADR, doxorubicin; VCR, vincristine; CPA, cyclophosphamide; IFO, ifosfamide; MTX, methotrexate; Ara-C, cytarabine; 6-MP, 6-mercaptopurine; 6-TG, thioguanine; RT, radiotherapy.